Colloidal silver "cure-all" OTC products not safe and effective -- FDA proposed rule.
This article was originally published in The Tan Sheet
Executive Summary
COLLOIDAL SILVER-CONTAINING OTC PRODUCTS LACK SAFETY/EFFICACY DATA and would be misbranded under a proposed rule published by FDA in an Oct. 15 Federal Register notice. Comments on whether the substance can be generally recognized as safe and effective (GRAS) may be submitted to the agency within 90 days. Colloidal silver historically has been marketed with claims to treat a number of disease conditions.
You may also be interested in...
Colloidal Silver Ingredients Not Safe, Effective In OTCs - FDA Final Rule
Rat studies showing no adverse effects from colloidal silver ingredients fail to demonstrate safety in humans, FDA says in a final rule declaring silver constituents in OTC drugs for internal or external use not generally recognized as safe and effective and misbranded.
Colloidal Silver Ingredients Not Safe, Effective In OTCs - FDA Final Rule
Rat studies showing no adverse effects from colloidal silver ingredients fail to demonstrate safety in humans, FDA says in a final rule declaring silver constituents in OTC drugs for internal or external use not generally recognized as safe and effective and misbranded.
Colloidal Silver Ingredients Not Safe, Effective In OTCs - FDA Final Rule
Rat studies showing no adverse effects from colloidal silver ingredients fail to demonstrate safety in humans, FDA says in a final rule declaring silver constituents in OTC drugs for internal or external use not generally recognized as safe and effective and misbranded.